Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 1 Clinical characteristics of CRC patients with nonresectable liver metastases.

From: Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy

Patient

Age (years)/sex

Response

Survival duration (months)

TS expression* before treatment

TS expression* after treatment

1

50/F

PD

4

4

11

2

70/M

PD

20

4

12

3

69/F

PD

17

5

21

4

61/M

PD

20

12

34

5

44/F

PD

27

15

47

6

53/M

PD

5

10

9

7

56/F

PD

9

23

ND

8

58/M

PD

7

14

ND

9

60/F

PD

13

15

ND

10

52/M

SD

11

9

14

11

79/M

SD

25

17

ND

12

49/F

SD

34

32

ND

13

63/M

SD

8

20

ND

14

56/F

SD

5

19

ND

15

51/F

PR

17

20

ND

16

65/M

PR

21

6

ND

17

55/M

PR

17

8

ND

18

70/M

PR

28

15

ND

19

73/F

PR

81

8

ND

20

65/M

CR

47

8

ND

  1. * This value is expressed in arbitrary units; F, female; M, male; PD, progression disease; SD, stable disease; PR, partial response; CR, complete response; ND, not determined.